|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquisition
|
gptkb:Tanabe_Seiyaku
gptkb:Mitsubishi_Pharma_Corporation
|
|
gptkbp:awards
|
various industry awards
|
|
gptkbp:ceo
|
Mr. Tanaka
|
|
gptkbp:clinical_trial
|
worldwide
global
ongoing
Phase II
Phase III
Phase I
|
|
gptkbp:collaborations
|
biotech companies
various universities
|
|
gptkbp:community_engagement
|
active
|
|
gptkbp:conducts_research_on
|
gptkb:Dr._John_Doe
|
|
gptkbp:employees
|
over 5,000
|
|
gptkbp:focus_area
|
gptkb:diabetes
neurology
oncology
cardiovascular diseases
immunology
|
|
gptkbp:founded
|
gptkb:2007
|
|
gptkbp:founder
|
gptkb:Mitsubishi_Group
|
|
gptkbp:global_presence
|
yes
|
|
gptkbp:grants
|
awarded
|
|
gptkbp:headquarters
|
gptkb:Osaka,_Japan
|
|
gptkbp:healthcare
|
FDA approved
EMA approved
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Mitsubishi Tanabe Pharma
|
|
gptkbp:instruction_set
|
multiple drugs
|
|
gptkbp:invention
|
numerous
|
|
gptkbp:investment
|
institutional investors
R& D
|
|
gptkbp:market
|
gptkb:Europe
gptkb:Japan
gptkb:United_States
|
|
gptkbp:market_cap
|
approximately $5 billion
|
|
gptkbp:parent_company
|
gptkb:Mitsubishi_Chemical_Holdings_Corporation
|
|
gptkbp:partnerships
|
healthcare organizations
|
|
gptkbp:produces
|
gptkb:Eculizumab
gptkb:Lonsurf
gptkb:Tazemetostat
gptkb:Radicava
gptkb:Tafasitamab
gptkb:Ninlaro
Dexamethasone
Mizoribine
Sustol
Revolade
|
|
gptkbp:products
|
gptkb:pharmaceuticals
|
|
gptkbp:research_areas
|
rare diseases
infectious diseases
|
|
gptkbp:research_focus
|
biologics
small molecules
|
|
gptkbp:revenue
|
over $1 billion
|
|
gptkbp:social_responsibility
|
active
|
|
gptkbp:specializes_in
|
research and development
|
|
gptkbp:stock_symbol
|
4508. T
|
|
gptkbp:subsidiaries
|
gptkb:Mitsubishi_Tanabe_Pharma_Europe
gptkb:Mitsubishi_Tanabe_Pharma_America
gptkb:Mitsubishi_Tanabe_Pharma_Asia
|
|
gptkbp:sustainability_initiatives
|
yes
|
|
gptkbp:training
|
ongoing
|
|
gptkbp:website
|
www.mt-pharma.co.jp
|
|
gptkbp:bfsParent
|
gptkb:Takeda
|
|
gptkbp:bfsLayer
|
4
|